Status of vaccine research and development of vaccines for malaria

Vaccine

Volumn 34, Issue 26, 2016, Pages 2915-2920

  Birkett, Ashley J ^a  

^a PATH Malaria Vaccine Initiative   (United States)

Author keywords

Elimination; Eradication; Malaria; Vaccine development

Indexed keywords

MALARIA VACCINE;

ARTICLE; FEASIBILITY STUDY; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HUMAN; MALARIA; MALARIA CONTROL; PARASITE CLEARANCE; PLASMODIUM; PRIORITY JOURNAL; VACCINATION; WORLD HEALTH ORGANIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); MEDICAL RESEARCH; MOSQUITO; PARASITOLOGY; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CULICIDAE; HUMANS; MALARIA; MALARIA VACCINES;

EID: 84962028877     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.074     Document Type: Article

References (19)

1. WHO World malaria report 2014, WHO.
2. Alonso P.L., Brown G., Arevalo-Herrera M., Binka F., Chitnis C., Collins F., et al. A research agenda to underpin malaria eradication. PLoS Med 2011, 8:e1000406. 10.1371/journal.pmed.1000406.
3. Tun K.M., Imwong M., Lwin K.M., Win A.A., Hlaing T.M., Hlaing T., et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 2015, 15:415-421. 10.1016/S1473-3099(15)70032-0.
4. Malaria vaccine technology roadmap 2006. http://www.malariavaccineroadmap.net/pdfs/Malaria_Vaccine_TRM_Final.pdf
5. Moorthy V.S., Newman R.D., Okwo-Bele J-M. Malaria vaccine technology roadmap. Lancet 2013, 382:1700-1701. 10.1016/S0140-6736(13)62238-2.
6. Birkett A.J., Moorthy V.S., Loucq C., Chitnis C.E., Kaslow D.C. Malaria vaccine R&D in the decade of vaccines: breakthroughs, challenges and opportunities. Vaccine 2013, 31(Supple):B233-B243. http://dx.doi.org/10.1016/j.vaccine.2013.02.040.
7. WHO WHO preferred product characteristics for malaria vaccines 2015, http://www.who.int/immunization/documents/innovation/WHO_IVB_14.09/en/ (accessed January 1, 2015).
8. WHO EP on I. Assessing the programmatic suitability of vaccine candidates for WHO prequalification 2012, http://apps.who.int/iris/bitstream/10665/76537/1/WHO_IVB_12.10_eng.pdf
9. Moran M., Guzman J., Chapman N., Whittall L.A-O.C., Howard R., Farrell P., et al. G-FINDER report 2014 2014.
10. Leach A., Vekemans J., Lievens M., Ofori-Anyinam O., Cahill C., Owusu-Agyei S., et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 2011, 10:224. 10.1186/1475-2875-10-224.
11. Outcomes of the first WHO Product Development for Vaccines Advisory Committee meeting. Geneva: 2014. http://www.who.int/immunization/sage/meetings/2014/october/4_pdvac_for_sage_key_outcomes_final_19oct.pdf
12. Tables on malaria vaccine projects globally 2015. http://www.who.int/immunization/research/development/Rainbow_tables/en/ (accessed April 1, 2015).
13. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875. 10.1056/NEJMoa1102287.
14. Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G.N.O., Kabwende A.L., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-2295. 10.1056/NEJMoa1208394.
15. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015. doi:10.1016/S0140-6736(15)60721-8.
16. Seder R.A., Chang L.-J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365. 10.1126/science.1241800.
17. Chuang I., Sedegah M., Cicatelli S., Spring M., Polhemus M., Tamminga C., et al. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS ONE 2013, 8:e55571. 10.1371/journal.pone.0055571.
18. Ewer K.J., O'Hara G.A., Duncan C.J.A., Collins K.A., Sheehy S.H., Reyes-Sandoval A., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4:2836. 10.1038/ncomms3836.
19. Hodgson S.H., Ewer K.J., Bliss C.M., Edwards N.J., Rampling T., Anagnostou N.A., et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 2015, 211:1076-1086. 10.1093/infdis/jiu579.